Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: A case report

17Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Hand-foot syndrome (HFS) is a well-known adverse event associated with capecitabine, a prodrug of 5-Fluorouracil (5-FU). HFS manifests as acral erythema, with swelling and dysesthesia of the palms and plantar aspects of the feet, which in the absence of dosage reduction or drug cessation, progresses to moist desquamation and ulceration, resulting in serious infections and loss of function. We report a case of HFS, with scleroderma-like changes, apparently induced by capecitabine. In our case, capecitabine, given in the recommended dosage was observed to lead to hyperpigmentation of the palms and soles, followed by a distinct keratoderma-like thickening unfamiliar to usual cases of HFS. This case may provide important clues for revising the definition of HFS, and allow the formation of effective preventive strategies for this side effect of chemotherapy.

Cite

CITATION STYLE

APA

Lee, S. D., Kim, H. J., Hwang, S. J., Kim, Y. J., Nam, S. H., & Kim, B. S. (2007). Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: A case report. Korean Journal of Internal Medicine, 22(2), 109–112. https://doi.org/10.3904/kjim.2007.22.2.109

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free